Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

What if a heart attack and lifetime of statin drugs could be avoided with a onetime, two-hour infusion? University of ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 ...

While the North Chicago, Illinois-based healthcare giant estimated its adjusted diluted earnings per share for Q3 could reach $1.28 - $1.32 compared to $1.33 in the consensus, its full-year outlook ...